RPTX (Repare Therapeutics) Moat Score: 5/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPTX Repare Therapeutics Inc RPTX
20 GF Score
Price $2.65
GF Value $0.94
! 6 Warning Signs
View Full Analysis

What is Repare Therapeutics Moat Score?

Repare Therapeutics RPTX 20 Moat Score is 5 as of Jul. 20, 2026. GuruFocus rates RPTX with a GF Score™ of 20/100 and a GF Value™ of $0.94. The stock has 6 warning signs investors should review.

Repare Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Repare Therapeutics has Narrow Moat: Repare Therapeutics Inc has a solid narrow moat due to its valuable intellectual property and strong R&D capabilities in oncology. However, it lacks the extensive market leadership and customer loyalty needed for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Repare Therapeutics might have Narrow Moat - Solid narrow moat.

Repare Therapeutics  (NAS:RPTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Repare Therapeutics Moat Score Related Terms

RPTX vs MGNX, THAR, ANIX: Moat Score Comparison

For the Biotechnology subindustry, Repare Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repare Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's Moat Score falls into.


RPTX
20GF Score
Repare Therapeutics Inc RPTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Repare Therapeutics (RPTX) has a Moat Score of 5 as of Jul. 20, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.
Is Repare Therapeutics' Moat Score too high?
Repare Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Repare Therapeutics' value of 5 is 150% above this industry median. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' Moat Score compare to MGNX and THAR?
Repare Therapeutics' Moat Score of 5 can be compared against companies in the Biotechnology industry. The industry median Moat Score is 2.00. Repare Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repare Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repare Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current Moat Score of 5. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current Moat Score is 5 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repare Therapeutics (RPTX) Overvalued in 2026?

Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued. The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.

Key valuation signals for RPTX:

  • Moat Score: 5
  • GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
  • GF Score™: 20/100 with 6 warning signs
  • Industry Position: 150% above the Biotechnology median

No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repare Therapeutics Business Description

Address 7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score

Get the complete analysis for RPTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.65
Price
$0.94
GF Value